BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

Core Insights - BioCardia, Inc. announced that echocardiography data for its CardiAMP Cell Therapy for heart failure has been accepted for presentation at the THT Meeting in March 2026 [1][2] Group 1: CardiAMP Cell Therapy - CardiAMP Cell Therapy is designed to use a patient's own bone marrow cells to improve heart function through a minimally invasive procedure [3] - The therapy aims to increase capillary density and reduce tissue fibrosis in myocardial tissue, addressing microvascular dysfunction [3] - The clinical development of CardiAMP is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS [3] Group 2: Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with multiple clinical-stage product candidates [4] - The company has developed biotherapeutic platforms, including CardiAMP and CardiALLO™, and utilizes advanced delivery systems like Helix™ and Morph [4] - BioCardia is actively seeking partnerships for biotherapeutic delivery with other companies in the biologic therapy space [4]